Impact of anti-CD20 monoclonal antibodies on serologic response to

Building better monoclonal antibody-based therapeutics

Synergistic anti-tumor therapy by a comb-like multifunctional antibody nanoarray with exceptionally potent activity

CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies - ScienceDirect

A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies

Vaccines, Free Full-Text

Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals after mRNA vaccination

Imaging the mechanisms of anti-CD20 therapy in vivo uncovers spatiotemporal bottlenecks in antibody-dependent phagocytosis

Imaging the mechanisms of anti-CD20 therapy in vivo uncovers spatiotemporal bottlenecks in antibody-dependent phagocytosis

B-cell subpopulations in humans and their differential susceptibility to depletionwith anti-CD20 monoclonal antibodies, Arthritis Research & Therapy

Neutralizing antibody against anti–SARS-CoV-2 vaccination

Three Anti-CD20 Antibodies: Rituximab, Ocrelizumab, and Ofatumumab.

British Journal of Haematology

Vaccines, Free Full-Text